France's Sanofi SA (SAN.FR) said Wednesday that it expects to begin at least ten phase 3 studies over the next 12 months, following a preview of its research-and-development strategy and pipeline for 2018.
The pharmaceutical company said that the studies will include evaluations of new treatments for chronic obstructive pulmonary disease and eosinophilic esophagitis, for autosomal dominant polycystic kidney disease and for type 2 diabetes.
Continue Reading Below
Sanofi said that in the next 12 months its regulatory filings are set to include two investigational cancer drugs--cemiplimab and isatuximab--a novel therapy for type 1 diabetes called sotagliflozin and a potential treatment for uncontrolled, persistent asthma called dupilumab.
In total, the company's pipeline includes 71 research-and-development projects, 37 of which are new molecular entities and novel vaccines.
Sanofi will host an analysts meeting later Wednesday to discuss its development pipeline and milestones for 2018 further.
Write to Anthony Shevlin at firstname.lastname@example.org
(END) Dow Jones Newswires
December 13, 2017 03:54 ET (08:54 GMT)